Table 2.
NF2 Patients Identified From UK Database, With and Without Radiation-Based Treatment
| No RT | No RT Matched | RT | P-value Matched Set | |
|---|---|---|---|---|
| Number of patients with NF2 | 1079 | 266 | 266 | |
| median age of NF2 diagnosis (years) | 33.0 | 28.0 | 28.5 | .98 |
| IQR | 18–50 | 19–43 | 18-44 | |
| median year birth | 1967 | 1971 | 1971 | .95 |
| IQR | 1952–1986 | 1957–1983 | 1958–1981 | |
| Mean age first symptom | 28.3 (missing n=190) | 27.07 | 28.10 | |
| median age treatment index tumor (years) | - | 31.3 | 32.9 | .366 |
| IQR | - | 22.7-45.0 | 22.4-46.0 | |
| Median time from NF2 diagnosis to treatment of index tumor (years) | 1.61 | 2.75 | ||
| IQR | 0.35–5.54 | 0.71–6.83 | ||
| Male | 499 | 133 | 133 | 1.0 |
| % | 46.3% | 50.0% | 50.0% | |
| Follow-up from NF2 diagnosis years | 12674.23 | 4580.54 | 4142.34 | |
| Mean follow-up from NF2diagnosis (years) | 11.75 | 17.22 | 15.57 | .04 |
| Median follow-up (years) | 9.56 | 15.92 | 14.85 | .13 |
| IQR | 5.1 – 16.9 | 9.3–24.0 | 8.9–22.1 | |
| Follow-up from treatment of index tumor years | - | 3778.12 | 2993.15 | |
| Mean follow-up from treatment (years) | - | 14.2 | 11.25 | <.001 |
| Median follow-up (years) | - | 11.9 | 9.83 | .005 |
| IQR | - | 5.8–20.0 | 4.1–16.6 | |
| CNS malignancy from date of treatment (number) | 5 (0.46%) | 0 | 9* (3.4%) | .004 |
| Sites RT/surgery | N/a | 208 VS 42 meningioma 15 spinal |
208 VS 42 meningioma 15 spinal |
1.0 |
| CNS malignancy types | 2 epithelioid sarcomas 3 grade 3 meningioma |
None -1 grade 3 meningioma but prior to matching |
4 MPNST/malignant schwannoma 2 grade 3 meningioma 1 glioblastoma 2 aggressive ependymoma |
|
| Died | 232 | 58 | 72 | .19 |
| % | 21.5% | 21.8% | 27.1% | |
| mean age death (years) | 47.05 | 47.86 | 42.69 | .07 |
| Median (years) | 44.68 | 45.79 | 39.75 | .07 |
| IQR | 30.2–63.5 | 35.9–59.5 | 30.8–51.2 | |
| CVA death | 4 | 0 | 2 | .50 |
| % deaths | 1.72% | 0% | 2.82% | |
| heterozygote PV | 535 | 160 | 139 | .08 |
| % Heterozygote | 49.58% | 60.1% | 52.3% | |
| Mosaic | 189 | 63 | 49 | .17 |
| % | 17.5% | 23.7% | 18.4% | |
| not found | 355 | 43 | 78 | .004 |
| % | 32.90% | 16.2% | 29.3% | |
| severe heterozygote PV | 137 | 47 | 39 | .28 |
| % | 12.7% | 17.7% | 14.7% |
RT-radiotherapy for benign/presumed benign disease; *-1 grade 3 meningioma excluded as occurred before RT and one MPNST, not in radiation volume; PV, pathogenic variant; IQR, interquartile range; VS, vestibular schwannoma; CVA, cerebrovascular accident (stroke).